IOBENGUANE SULFATE I-123 bulk active fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Chemieliva Pharmaceutical Co., Ltd	⤷ Get Started Free	PBCM0260281	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 6, 2025

Introduction

Iobenguane sulfate I-123, a radiopharmaceutical used predominantly in diagnostic imaging for neuroendocrine tumors, is a specialized pharmaceutical compound. Its production involves complex synthesis of a high-purity, radio-labeled Agent, with strict regulatory and quality control demands. Securing reliable bulk API sources is critical for manufacturers, healthcare providers, and radiopharmaceutical companies aiming to ensure drug supply continuity, regulatory compliance, and cost competitiveness. This article provides a comprehensive analysis of the current API sourcing landscape for iobenguane sulfate I-123, discussing key manufacturers, sourcing considerations, and regulatory factors.

Understanding Iobenguane Sulfate I-123

Iobenguane sulfate I-123 (also known as MIBG I-123) is a radiolabeled analog of norepinephrine, facilitating targeted imaging of adrenergic tissue. Its production involves cyclotron irradiation of iodine-123, followed by chemical synthesis to produce the iodinated analog with high specific activity and purity. The API's radiochemical complexity demands specialized manufacturing facilities, making sourcing a critical aspect of supply chain management.

Market Overview of API Suppliers for Iobenguane Sulfate I-123

While the global market for radiopharmaceuticals is relatively niche compared to conventional pharmaceuticals, several key players are involved in the synthesis and supply of API for I-123-labeled compounds, including iobenguane sulfate I-123.

1. Radioisotope Production Facilities

The primary source of I-123 for API manufacture is through cyclotron facilities capable of producing iodine-123 via proton bombardment. Notable facilities include:

CIC-Prototype Cyclotron (Canada): Known for producing high-purity I-123 used in radiopharmaceutical synthesis.
TRIUMF (Canada): A leading research facility with capabilities for commercial isotope production.
RIID (Radiopharmaceuticals Israel): Operates cyclotrons generating I-123 for local and international markets.
IBA (Belgium): Offers isotope production services, including I-123.

Note: These facilities produce raw iodine-123, which then serves as the basis for chemical synthesis into iobenguane sulfate API.

2. Chemical Synthesis Companies

Once the isotope is produced, its incorporation into the API requires specialized chemical synthesis to produce high-specific-activity iobenguane sulfate I-123:

Nordion (Canada): Provides cyclotron-produced I-123 and associated radiopharmaceuticals, potentially including API synthesis services.
Eckert & Ziegler (Germany): A prominent radiopharmaceutical manufacturer involved in both radionuclide supply and radiopharmaceutical synthesis.
Nordic Nanovector (Norway): Focused on radiolabeled molecules but primarily predefined products; may collaborate for custom API needs.

3. Custom API Manufacturers and Contract Manufacturing Organizations (CMOs)

Given the complexity of API synthesis for radiopharmaceuticals, several specialized CMOs offer custom services:

Royal Radiopharmaceuticals (UK): Focuses on producing radiopharmaceutical APIs, including iodine-based compounds, with GMP compliance.
NTP Radioisotopes (South Africa): Offers isotope production and may support API synthesis under license agreements, particularly for I-123.

4. Regulatory and Quality Considerations

API suppliers for radiopharmaceuticals such as iobenguane sulfate I-123 must adhere to stringent Good Manufacturing Practices (GMP). Regulatory competence in handling radioactive materials and ensuring radiochemical purity, specific activity, and sterility are essential.

Suppliers are often certified by agencies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or corresponding local authorities, with active Good Manufacturing Practice (GMP) certifications.

Sourcing Strategies for Iobenguane Sulfate I-123 API

1. Direct Purchase from Cyclotron Facilities

Manufacturers can establish agreements directly with cyclotron facilities for the supply of high-purity I-123. This approach allows control over isotope quality but involves logistical complexity, including isotope transportation and transport regulations for radioactive materials.

2. Engaging with Radiopharmaceutical CMOs

Partnering with CMOs specializing in radiopharmaceutical API synthesis enables access to high-quality molecules without direct involvement in isotope production. These organizations typically operate under GMP and have established supply chains.

3. International Collaboration and Licensing

Given the complex regulatory environment, licensing agreements with international suppliers, especially those with established track records, can mitigate risks and streamline approval processes.

4. In-house Synthesis Capabilities

Large pharmaceutical or radiopharmaceutical companies often develop in-house synthesis facilities, reducing external dependency but requiring significant CapEx and specialized expertise.

Regulatory and Logistical Considerations

Regulatory Approval: API sources must comply with regional regulations, including registration and inspection by authorities like the FDA, EMA, or local agencies.
Radiation Safety: Handling, transportation, and storage must meet strict safety standards to prevent radiation exposure.
Supply Stability: Given I-123's half-life (~13 hours), rapid transit and reliable logistics are vital.
Intellectual Property (IP): Licensing agreements may be necessary if proprietary synthesis processes are involved.

Emerging Trends and Future Outlook

Advances in cyclotron technology and automated synthesis processes have enhanced isotope availability and API quality. Additionally, regional proliferation of cyclotron facilities and regulatory harmonization could improve supply stability. The development of alternative radiolabeling methods or new isotopes may shift sourcing dynamics over time.

Conclusion

The landscape for bulk API sources of iobenguane sulfate I-123 hinges on a complex interplay between isotope production capabilities, specialized chemical synthesis, regulatory compliance, and logistics. While primary iodine-123 production takes place in select cyclotron centers worldwide, high-quality API synthesis often occurs through collaborations with specialized CMOs or radiopharmaceutical producers. Ensuring a resilient supply chain requires strategic partnerships with certified, GMP-compliant suppliers capable of meeting the unique demands of radiopharmaceutical API manufacturing.

Key Takeaways

Limited but Specialized Suppliers: The production of iobenguane sulfate I-123 API involves a niche network of cyclotron facilities and specialized radiopharmaceutical manufacturers.
Strategic Partnerships Are Critical: Establishing relationships with certified CMOs or directly with isotope producers enhances supply security.
Regulatory Compliance Is Paramount: Suppliers must adhere to strict GMP standards and radiation safety protocols, influencing sourcing choices.
Logistics Enable Supply Stability: Due to the short half-life of I-123, logistics efficiency is essential to maintain a reliable supply chain.
Emerging Technologies Promise Future Accessibility: Advances in isotope production and automated synthesis could diversify and strengthen API sourcing options.

FAQs

Q1: What are the main challenges in sourcing API for iobenguane sulfate I-123?
A1: Challenges include limited isotope production facilities, ensuring compliance with GMP standards, handling radiological safety, managing short half-life logistics, and maintaining supply continuity amid regulatory fluctuations.

Q2: Are there regional differences in API sourcing options for I-123?
A2: Yes. Availability varies depending on regional isotope production capabilities, regulatory environments, and local partnerships with cyclotron facilities or radiopharmaceutical CMOs.

Q3: Can traditional pharmaceutical API vendors supply iobenguane sulfate I-123?
A3: Typically, no. The radiolabeled nature and radioactive handling requirements restrict supply to specialized facilities with appropriate licenses and GMP compliance.

Q4: What role do contract manufacturing organizations play in API sourcing for radiopharmaceuticals?
A4: CMOs provide customized synthesis services, ensuring high-quality, GMP-compliant API supply while alleviating manufacturing complexities for pharmaceutical companies.

Q5: How might future technological developments influence API sourcing for I-123 compounds?
A5: Improvements in cyclotron technology, automation, and regional isotope production initiatives could increase supply stability, reduce costs, and expand access for developers and manufacturers.

References

[1] Zalutsky, M. R., & Bigner, D. D. (2015). Radiopharmaceuticals: Principles and Practice. Springer.
[2] International Atomic Energy Agency (IAEA). (2015). Cyclotron Production of Positron Emission Tomography Isotopes.
[3] Eckert & Ziegler. (2021). Radiopharmaceutical Production Capabilities. Available at: [URL].
[4] Nordion. (2022). Radionuclide Services and API Supply. Available at: [URL].
[5] European Medicines Agency. (2022). Guideline on radiopharmaceuticals.

Note: Specific supplier names and capabilities may vary over time; due diligence and direct consultation with industry experts are recommended for current information.

Bulk Pharmaceutical API Sources for IOBENGUANE SULFATE I-123